

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)				ATTY. DOCKET NO.: 0-2002.724US		SERIAL NO.: 10/510,275	
				APPLICANT: PEDRO H. H. HERMKENS			
				EXAMINER NAME: BRENDA LIBBY COLEMAN			
				FILING DATE: 03/11/2005		ART UNIT: 1624	
Sheet 1 of 2							
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CITE NO. ¹	DOCUMENT NUMBER	PUB. DATE. mm-dd-yyyy	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T ⁶
/B.C./	AA	3,966,723	06/29/1976	van der Burg			
/B.C./	AB	4,054,572	10/18/1977	van der Burg			
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL	CITE NO. ¹	DOCUMENT NUMBER	PUB. DATE. mm-dd-yyyy	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T ⁶
** /B.C./	AC	DE 2420168 Which corresponds to US 3,966,723 & US 4,054,572	04/25/1974	Akzo N.V.			
**/B.C./	AD	EP 0 876815	11/11/1998	Akzo Nobel N.V.			
/B.C./	AE	WO 03/084963	10/16/2003	Akzo Nobel N.V.			
/B.C./	AF	WO 2006/084917	08/17/2006	Akzo Nobel N.V.			
/B.C./	AG	WO 2008/037746	04/03/2008	N.V. Organon			
Examiner signature: /Brenda Coleman/				Date considered: 01/27/2010			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.

This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**** structures only**

SUBSTITUTE FOR FORM 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		ATTY. DOCKET NO.: 0-2002.724US SERIAL NO.: 10/510,275 APPLICANT: PEDRO H.H. HERMKENS EXAMINER NAME: BRENDA LIBBY COLEMAN FILING DATE: 03/11/2005 ART UNIT: 1624	
Sheet 2 of 2			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.C./	AH	CAUFIELD, W., "Synthesis of 1-amino-1,2,3,14b-tetrahydro-4H-pyrido[1,2-d]-dibenzo[b,f][1,4]oxazepine and related compounds", <i>J. Chem. Soc., Perkins Trans. 1</i> , No. 6, pgs. 545-553, (1996)	
/B.C./	AI	DIJKEMA, R., et al., "Human Progesterone Receptor A and B Isoforms in CHO cells. I. Stable Transfection of Receptor and Receptor-responsive Reporter Genes: Transcription Modulation by (Anti)progestagens", <i>J. Steroid Biochem. Biol.</i> , Vol. 64, No. 3-4, pgs. 147-156 (1998)	
/B.C./	AJ	SCHOONEN, W., et al., "Development of High-Throughput in Vitro Bioassay to Assess Potencies of Progestagenic Compounds Using Chinese Hamster Ovary Cells Stably Transfected with the Human Progesterone Receptor and a Luciferase Reporter System", <i>Analytical Biochemistry</i> , Vol. 261, pgs. 222-224 (1998)	
/B.C./	AK	PCT International Search Report dated <u>08/06/2003</u> for corresponding PCT Application No. PCT/EP03/50085	
/B.C./	AL	PCT International Search Report and Written Opinion, dated <u>August 12, 2008</u> , which was issued during the prosecution of International Application No. PCT/EP2008/003714, which is related to the present application.	
/B.C./	AM	PCT International Search Report and Written Opinion, dated <u>December 28, 2007</u> , which was issued during the prosecution of International Application No. PCT/EP2007/060225, which is related to the present application	
Examiner signature:		Date considered:	
/Brenda Coleman/		01/27/2010	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.